PMCB (PharmaCyte Biotech) Current Accrued Expense: $0.56 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMCB PharmaCyte Biotech Inc PMCB
33 GF Score
Price $0.51
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Current Accrued Expense?

PharmaCyte Biotech PMCB -3.33% 33 Current Accrued Expense is $0.56 Mil as of Apr. 2026. GuruFocus rates PMCB with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Current Accrued Expense for the quarter that ended in Apr. 2026 was $0.56 Mil.

PharmaCyte Biotech's quarterly Current Accrued Expense declined from Oct. 2025 ($0.52 Mil) to Jan. 2026 ($0.45 Mil) but then increased from Jan. 2026 ($0.45 Mil) to Apr. 2026 ($0.56 Mil).

PharmaCyte Biotech's annual Current Accrued Expense increased from Apr. 2024 ($0.40 Mil) to Apr. 2025 ($2.49 Mil) but then declined from Apr. 2025 ($2.49 Mil) to Apr. 2026 ($0.56 Mil).

PharmaCyte Biotech Current Accrued Expense Related Terms

PharmaCyte Biotech Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Current Accrued Expense Chart

PharmaCyte Biotech Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.40 0.40 2.49 0.56

PharmaCyte Biotech Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 0.60 0.52 0.45 0.56
PMCB
33GF Score
PharmaCyte Biotech Inc PMCB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.56 Mil mean?
PharmaCyte Biotech (PMCB) has a Current Accrued Expense of $0.56 Mil as of Apr. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Current Accrued Expense too high?
PharmaCyte Biotech's current Current Accrued Expense is $0.56 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Current Accrued Expense compare to NIKI and IMNN?
PharmaCyte Biotech's Current Accrued Expense of $0.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Current Accrued Expense is $0.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Current Accrued Expense of $0.56 Mil. The current Current Accrued Expense is $0.56 Mil. PharmaCyte Biotech's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Current Accrued Expense is $0.56 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
33GF Score

Get the complete analysis for PMCB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.51
Price